Literature DB >> 19188551

Association of the metabolic syndrome with pulmonary venous hypertension.

Ivan M Robbins1, John H Newman2, Roger F Johnson2, Anna R Hemnes2, Richard D Fremont2, Robert N Piana3, David X Zhao3, Daniel W Byrne4.   

Abstract

BACKGROUND: Pulmonary venous hypertension (PVH) is a well-described cause of pulmonary hypertension (PH) in patients with left heart disease associated with elevated left heart filling pressure. PVH results from a number of processes, including left-sided valvular disease, constrictive pericardial disease, restrictive cardiomyopathies, and left ventricular (LV) systolic dysfunction. PVH in patients with normal LV systolic function, commonly referred to as diastolic dysfunction, is not well characterized. We observed that many patients with PH due to PVH have obesity, hypertension, diabetes mellitus, and hypercholesterolemia, which are clinical features of the metabolic syndrome (MS), a previously identified cause for systemic vascular disease.
METHODS: We evaluated 122 consecutive patients referred for diagnosis and treatment of PH and compared the prevalence of features of the MS between patients with PVH and those with pulmonary arterial hypertension (PAH). We also compared clinical and hemodynamic characteristics between these two groups.
RESULTS: Compared to patients with PAH, patients with PVH had a higher frequency of hypertension, obesity, diabetes mellitus, and hyperlipidemia. Two or more features of the MS were found in 16 of 17 patients with PVH (94.1%) compared with 34.3% of patients with PAH (p < 0.001; odds ratio, 30.7; 95% confidence interval, 3.6 to 260.0). PH was substantial, but less severe overall, in patients with PVH compared to those with PAH (mean pulmonary artery pressure, 45 +/- 17 mm Hg [range, 26 to 71 mm Hg] vs 53 +/- 10 [range, 33 to 72 mm Hg], respectively [p = 0.041]; and pulmonary vascular resistance, 4.4 +/- 2.9 units [range, 1.2 to 10.8 units] vs 10.8 +/- 4.7 units [range, 4.8 to 21.9 units], respectively [p < 0.001]).
CONCLUSION: PVH is highly associated with the MS. Our results suggest that the MS may predispose patients to develop pulmonary vascular disease.

Entities:  

Mesh:

Year:  2009        PMID: 19188551      PMCID: PMC2716716          DOI: 10.1378/chest.08-2008

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  24 in total

1.  Clinical profile and outcome of idiopathic restrictive cardiomyopathy.

Authors:  N M Ammash; J B Seward; K R Bailey; W D Edwards; A J Tajik
Journal:  Circulation       Date:  2000-05-30       Impact factor: 29.690

Review 2.  Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition.

Authors:  Scott M Grundy; H Bryan Brewer; James I Cleeman; Sidney C Smith; Claude Lenfant
Journal:  Circulation       Date:  2004-01-27       Impact factor: 29.690

Review 3.  Clinical classification of pulmonary hypertension.

Authors:  Gerald Simonneau; Nazzareno Galiè; Lewis J Rubin; David Langleben; Werner Seeger; Guido Domenighetti; Simon Gibbs; Didier Lebrec; Rudolf Speich; Maurice Beghetti; Stuart Rich; Alfred Fishman
Journal:  J Am Coll Cardiol       Date:  2004-06-16       Impact factor: 24.094

4.  Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey.

Authors:  Earl S Ford; Wayne H Giles; William H Dietz
Journal:  JAMA       Date:  2002-01-16       Impact factor: 56.272

Review 5.  Diagnosis and differential assessment of pulmonary arterial hypertension.

Authors:  Robyn J Barst; Michael McGoon; Adam Torbicki; Olivier Sitbon; Michael J Krowka; Horst Olschewski; Sean Gaine
Journal:  J Am Coll Cardiol       Date:  2004-06-16       Impact factor: 24.094

6.  Trends and correlates of class 3 obesity in the United States from 1990 through 2000.

Authors:  David S Freedman; Laura Kettel Khan; Mary K Serdula; Deborah A Galuska; William H Dietz
Journal:  JAMA       Date:  2002-10-09       Impact factor: 56.272

7.  Hospitalization for heart failure in the presence of a normal left ventricular ejection fraction: results of the New York Heart Failure Registry.

Authors:  Marc Klapholz; Matthew Maurer; April M Lowe; Frank Messineo; Jay S Meisner; Judith Mitchell; Jill Kalman; Robert A Phillips; Richard Steingart; Edward J Brown; Robert Berkowitz; Robert Moskowitz; Anita Soni; Donna Mancini; Rachel Bijou; Khashayar Sehhat; Nikita Varshneya; Marrick Kukin; Stuart D Katz; Lynn A Sleeper; Thierry H Le Jemtel
Journal:  J Am Coll Cardiol       Date:  2004-04-21       Impact factor: 24.094

8.  Constrictive pericarditis: etiology and cause-specific survival after pericardiectomy.

Authors:  Stefan C Bertog; Senthil K Thambidorai; Kapil Parakh; Paul Schoenhagen; Volkan Ozduran; Penny L Houghtaling; Bruce W Lytle; Eugene H Blackstone; Michael S Lauer; Allan L Klein
Journal:  J Am Coll Cardiol       Date:  2004-04-21       Impact factor: 24.094

9.  Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic.

Authors:  Margaret M Redfield; Steven J Jacobsen; John C Burnett; Douglas W Mahoney; Kent R Bailey; Richard J Rodeheffer
Journal:  JAMA       Date:  2003-01-08       Impact factor: 56.272

10.  Pulmonary artery pressure and diastolic dysfunction in normal left ventricular systolic function.

Authors:  Yoram Neuman; Andy Kotliroff; Tamir Bental; Robert J Siegel; Daniel David; Michael Lishner
Journal:  Int J Cardiol       Date:  2007-07-23       Impact factor: 4.164

View more
  64 in total

1.  Peripheral blood signature of vasodilator-responsive pulmonary arterial hypertension.

Authors:  Anna R Hemnes; Aaron W Trammell; Stephen L Archer; Stuart Rich; Chang Yu; Hui Nian; Niki Penner; Mitchell Funke; Lisa Wheeler; Ivan M Robbins; Eric D Austin; John H Newman; James West
Journal:  Circulation       Date:  2014-10-31       Impact factor: 29.690

Review 2.  Strategic plan for lung vascular research: An NHLBI-ORDR Workshop Report.

Authors:  Serpil Erzurum; Sharon I Rounds; Troy Stevens; Micheala Aldred; Jason Aliotta; Stephen L Archer; Kewal Asosingh; Robert Balaban; Natalie Bauer; Jahar Bhattacharya; Harm Bogaard; Gaurav Choudhary; Gerald W Dorn; Raed Dweik; Karen Fagan; Michael Fallon; Toren Finkel; Mark Geraci; Mark T Gladwin; Paul M Hassoun; Marc Humbert; Naftali Kaminski; Steven M Kawut; Joseph Loscalzo; Donald McDonald; Ivan F McMurtry; John Newman; Mark Nicolls; Marlene Rabinovitch; Judy Shizuru; Masahiko Oka; Peter Polgar; David Rodman; Paul Schumacker; Kurt Stenmark; Rubin Tuder; Norbert Voelkel; Eugene Sullivan; Richard Weinshilboum; Mervin C Yoder; Yingming Zhao; Dorothy Gail; Timothy M Moore
Journal:  Am J Respir Crit Care Med       Date:  2010-09-10       Impact factor: 21.405

Review 3.  Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies.

Authors:  Stephen L Archer; E Kenneth Weir; Martin R Wilkins
Journal:  Circulation       Date:  2010-05-11       Impact factor: 29.690

4.  International Classification of Diseases coding changes lead to profound declines in reported idiopathic pulmonary arterial hypertension mortality and hospitalizations: implications for database studies.

Authors:  Jeffrey Link; Craig Glazer; Fernando Torres; Kelly Chin
Journal:  Chest       Date:  2010-08-19       Impact factor: 9.410

Review 5.  Metabolic Syndrome and the Lung.

Authors:  Cynthia W Baffi; Lisa Wood; Daniel Winnica; Patrick J Strollo; Mark T Gladwin; Loretta G Que; Fernando Holguin
Journal:  Chest       Date:  2016-01-20       Impact factor: 9.410

6.  Unrecognized glucose intolerance is common in pulmonary arterial hypertension.

Authors:  Meredith E Pugh; Ivan M Robbins; Todd W Rice; James West; John H Newman; Anna R Hemnes
Journal:  J Heart Lung Transplant       Date:  2011-04-13       Impact factor: 10.247

Review 7.  Pulmonary hypertension in women.

Authors:  Meredith E Pugh; Anna R Hemnes
Journal:  Expert Rev Cardiovasc Ther       Date:  2010-11

Review 8.  Enterosalivary nitrate metabolism and the microbiome: Intersection of microbial metabolism, nitric oxide and diet in cardiac and pulmonary vascular health.

Authors:  Carl D Koch; Mark T Gladwin; Bruce A Freeman; Jon O Lundberg; Eddie Weitzberg; Alison Morris
Journal:  Free Radic Biol Med       Date:  2016-12-16       Impact factor: 7.376

9.  Use of pulmonary arterial hypertension-approved therapy in the treatment of non-group 1 pulmonary hypertension at US referral centers.

Authors:  Aaron W Trammell; Meredith E Pugh; John H Newman; Anna R Hemnes; Ivan M Robbins
Journal:  Pulm Circ       Date:  2015-06       Impact factor: 3.017

10.  High prevalence of occult pulmonary venous hypertension revealed by fluid challenge in pulmonary hypertension.

Authors:  Ivan M Robbins; Anna R Hemnes; Meredith E Pugh; Evan L Brittain; David X Zhao; Robert N Piana; Pete P Fong; John H Newman
Journal:  Circ Heart Fail       Date:  2013-12-02       Impact factor: 8.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.